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[h1]Abstract 1 
Cardiac arrest effectiveness trials have traditionally reported outcomes that focus on survival. 2 
A lack of consistency in outcome reporting between trials limits the opportunities to pool 3 
results for meta-analysis. The Core Outcome Set for Cardiac Arrest (COSCA) initiative, a 4 
partnership between patients, their partners, clinicians, research scientists, and the 5 
International Liaison Committee on Resuscitation, sought to develop a consensus core 6 
outcome set for cardiac arrest for effectiveness trials. Core outcome sets are primarily 7 
intended for large, randomized clinical effectiveness trials (sometimes referred to as 8 
pragmatic trials, phase III/IV trials) rather than for pilot or efficacy studies. 9 
 10 
A systematic review of the literature combined with qualitative interviews among cardiac 11 
arrest survivors was used to generate a list of potential outcome domains. This list was 12 
prioritized through a Delphi process, which involved clinicians, patients, and their 13 
relatives/partners. An international advisory panel narrowed these down to 3 core domains by 14 
debate leading to consensus. The writing group refined recommendations for when these 15 
outcomes should be measured and further characterized relevant measurement tools. 16 
 17 
Consensus emerged that a core outcome set for reporting on effectiveness studies of cardiac 18 
arrest (COSCA) in adults should include survival, neurologic function, and health-related 19 
quality of life. This should be reported as survival status and modified Rankin Scale score at 20 
hospital discharge and / or 30 days. Health-related quality of life should be measured by 21 
using 1 or more tools from Health Utilities Index version 3, Short-Form 36-Item Health 22 
Survey, EuroQol 5D-5L at 90 days and at periodic intervals up to 1 year after cardiac arrest, 23 
if resources allow.  24 
 25 
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[h1]Introduction 1 
Sudden cardiac arrest is one of the leading causes of death in industrialized nations. In the 2 
United States, approximately 360 000 cardiac arrests are attended by emergency services 3 
each year, with only 10.6% of patients surviving to hospital discharge.1 Similar statistics 4 
apply across Europe and all other industrialized areas worldwide.2, 3 However, survival rates 5 
vary widely both globally4 and regionally,5, 6 with 4-fold or more regional variations reported. 6 
These low and variable survival rates highlight the importance of research that seeks to 7 
improve patient outcomes. 8 
 9 
Randomized trials are important tools for evaluating the clinical and cost-effectiveness of 10 
interventions for in- and out-of-hospital cardiac arrest. Two broad types of trials have been 11 
described—efficacy and effectiveness. Efficacy (sometimes called explanatory) trials aim to 12 
test whether an intervention works under optimal situations. Effectiveness (sometimes called 13 
pragmatic) trials are designed to assess how well an intervention works in routine clinical 14 
practice.7 Ordinarily, efficacy trials focus on assessing the impact of an intervention on a 15 
short-term outcome that is well-correlated with long-term prognosis. Effectiveness trials seek 16 
to provide evidence of the longer-term health impact of an intervention.8, 9 Evaluated 17 
outcomes may include clinical, clinician-reported, and patient-reported outcomes and 18 
resource use or economic impact. Clinical trials provide essential evidence of the relative 19 
benefit of an intervention for stakeholders as diverse as clinicians, patients, and policy 20 
makers. Outcome selection is, therefore, an important aspect of trial design.9, 10 21 
 22 
Sometimes multiple trials may evaluate the same intervention in different settings. 23 
Reconciling disparate trial results can be challenging if each trial evaluated different 24 
outcomes at different timepoints. A systematic review of cardiac arrest trials published 25 
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between 2000 and 2012 included 61 publications that identified more than 160 different trial 1 
outcomes.11 No single outcome was reported across all trials. The majority of outcomes 2 
reflected short-term clinical and clinician-reported outcomes, focusing on pathophysiologic 3 
manifestations and process-based measures. While survival was the most commonly reported 4 
outcome, 39 different definitions of survival were used. Patient-reported outcomes12 were 5 
rarely reported, although more recent trials have included these outcomes.13, 14 This suggests 6 
that essential evidence of the impact of care from the survivors’ perspective is currently 7 
missing from clinical trials.  8 
 9 
Adopting a consistent approach to outcome reporting for effectiveness trials has the potential 10 
to reduce heterogeneity in reporting, improve transparency in outcome selection, reduce 11 
reporting bias, and increase information available to pool for meta-analysis. Standardized 12 
reporting frameworks have been developed for reporting the findings of observational studies 13 
drawn from resuscitation registries.15, 16 These recommend 23 core data elements and 30 14 
supplementary elements across the 5 domains of system, dispatch, patient, process, and 15 
outcome.17 International guidelines exist for core outcomes to use in effectiveness trials in 16 
patients with other conditions.18 Becker et al considered choices of primary outcomes across 17 
a range of resuscitation science studies but concluded that no single primary outcome was 18 
appropriate for all studies of cardiac arrest.19 However, no international guidelines exist to 19 
define a focused core outcome set (COS) for use in effectiveness trials in patients with 20 
cardiac arrest.  21 
 22 
The Core Outcome Measures for Effectiveness Trials (COMET) initiative promotes the 23 
development and application of agreed standardized sets of outcomes, known as core 24 
outcome sets.20 25 
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A COS is defined as a small, standardized group of outcomes that should be measured and 1 
reported, as a minimum, in all effectiveness trials for a specific health area.20, 21 Effectiveness 2 
trials should aim to capture the COS as part of their a priori‒defined primary or secondary 3 
outcomes. 4 
 5 
The COSCA initiative, in collaboration with the International Liaison Committee on 6 
Resuscitation (ILCOR), sought to develop a COS for cardiac arrest effectiveness trials 7 
covering both in- and out-of-hospital cardiac arrest. This consensus paper draws on the views 8 
and experiences of patients, the public, clinicians, policy makers, researchers, and the 9 
international perspectives represented through the ILCOR collaborative network. The process 10 
was informed by systematic reviews of the literature, as well as qualitative research involving 11 
cardiac arrest survivors. A total of 168 participants used a Delphi process to draft a core 12 
cardiac arrest outcome set, and a 2-day meeting was convened to develop consensus 13 
recommendations.  14 
[h1]Methods 15 
The available evidence associated with the development of COSs18, 20 and the websites of key 16 
COS development groups (COMET and Outcome Measures in Rheumatoid Arthritis Clinical 17 
Trials [OMERACT], later renamed Outcome Measures in Rheumatology) informed our 18 
approach. The project was registered with the COMET initiative (www.comet-19 
initiative.org/studies/details/284). Ethical approval was obtained from the National Health 20 
Service Black Country Research Ethics Committee (13/WM/0464) to enable patients/partners 21 
to participate. 22 
 23 
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Development of a COS involved 2 key steps: development of a core domain set (ie, what to 1 
measure) followed by identification of appropriate measurement tools (ie, how to measure).18, 2 
20 A core domain set was defined as referring to the minimum number of health domains 3 
(outcomes or aspects of health) that must be assessed. That is, it specifies what should be 4 
measured. Importantly, this stage was driven by what is important and not how an outcome is 5 
assessed. The second stage involved the establishment of a core outcome measurement set, 6 
that is, the specific methods of assessment (ie, how to measure) for the domains identified in 7 
step 1. The selection of measurement tools was informed by an appraisal of measurement 8 
quality, relevance, and feasibility. 9 
 10 
The OMERACT initiative suggests that a COS should seek to include at least 1 health 11 
domain across each of 4 core areas of health (Figure 1): 3 core areas consider the impact of a 12 
health condition (ie, survival, life impact, economic impact/resource use), and the fourth core 13 
area reflects any pathophysiologic manifestations associated with the condition.18 Several 14 
reviews11, 22, 23 suggest that these domains are relevant and encompass the large number of 15 
outcomes assessed in cardiac arrest trials. 16 
 17 
To develop the consensus outcome criteria, a 4-stage approach was used, which consisted of 18 
the following steps, which are each explained in detail:  19 
 Stage 1: Generation of an extensive list of potential outcomes across 4 core areas of 20 
health 21 
 Stage 2: International Delphi to refine and prioritize a list of potential outcomes 22 
 Stage 3: International expert panel meeting 23 
 Stage 4: Synthesis of findings and recommendations for measurement tools 24 
 25 
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[h2]Stage 1: Generation of an Extensive List of Potential Outcomes Across 4 Core Areas 1 
of Health 2 
This stage was informed by a systematic review of the literature and qualitative interviews 3 
with cardiac arrest survivors and their partners. The systematic review focused on the 4 
identification of outcomes reported from randomized controlled trials that enrolled adults 5 
who had sustained a cardiac arrest.11 The findings from the systematic review were 6 
supplemented by conducting semi-structured interviews with adult cardiac arrest survivors 7 
(and, if available, their partners) between 3 and 12 months after discharge from hospital 8 
following their cardiac arrest. Interviews were conducted, recorded, and transcribed by using 9 
NVivo (QSR International 2012) by L.W. Data were analyzed by using Interpretative 10 
Phenomenological Analysis, which seeks to capture the individuals’ experience of a 11 
phenomenon and how they understand their experiences.24 Findings from the systematic 12 
review and qualitative research were synthesized to produce an extensive list of potential 13 
outcomes. These were grouped under the OMERACT core area headings of survival, life 14 
impact, resource use/economic, and pathophysiologic manifestations of cardiac arrest for 15 
consideration in stage 2.  16 
 17 
[h2]Stage 2: International Delphi to Refine and Prioritize List of Potential Outcomes 18 
The list of potential outcomes identified during stage 1 were placed into an online survey tool 19 
(SurveyMonkey, Dublin, Ireland). Separate surveys were developed for healthcare 20 
professionals and patients/patient advocates. The ILCOR network of 7 regional resuscitation 21 
councils was used to solicit the views of healthcare professionals and patient and public 22 
advocates. Each ILCOR member (n=27) was asked to invite 6 healthcare professionals and 3 23 
patients to participate in the relevant surveys by email. The outcomes were prioritized in 2 24 
rounds. Questions were structured to allow participants to rate the importance of each 25 
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outcome at 5 different time points across the patient journey: during cardiopulmonary 1 
resuscitation (CPR), immediately after CPR, during hospitalization, at hospital discharge, and 2 
within the first year after the cardiac arrest. In the first round, survey participants were also 3 
given the opportunity to suggest additional outcomes they considered important if they were 4 
not currently included in the survey. At the end of each round, outcomes rated as critical 5 
importance by greater than 70% of respondents and rated as limited importance by less than 6 
15% of respondents were advanced for additional consideration by the expert panel in stage 7 
3. Similarly, those outcomes rated of limited importance by greater than 70% of respondents 8 
and of critical importance by less than 15% of respondents were discarded. The findings 9 
from the first round were summarized and presented for a second round of prioritization. Any 10 
new suggestions were included in the second round. The second round of prioritization 11 
differed by asking participants to rank outcomes according to importance. Outcomes that 12 
received strong support (more than 70% agreement) were also advanced for consideration by 13 
the expert panel in stage 3. Outcomes that received moderate support (60%–69% agreement) 14 
were also presented to the expert panel in stage 3. 15 
 16 
[h2]Stage 3: International Expert Panel Meeting 17 
The aim of the international expert panel was to consider the shortlist of outcomes identified 18 
during stage 2 and select a COS comprising 4 to 8 outcomes and make recommendations of 19 
measurement tools to capture those outcomes. A 2-day consensus meeting was convened in 20 
Prague, Czech Republic, in October 2015. A group of experts uninvolved in previous stages 21 
was purposefully selected to capture those involved in clinical research (clinicians, clinical 22 
trialists, methodologists), experts in the use of measurement tools for cardiac arrest, 23 
healthcare providers involved in treating patients with cardiac arrest (physicians, nurses, 24 
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paramedics, allied health professionals), and survivors of cardiac arrests and patient 1 
advocates.  2 
 3 
Before the meeting, the participants were sent a written summary of the outcome selection 4 
process described above. At the start of the meeting, an overview of steps undertaken and 5 
findings from stages 1 and 2 were presented. The shortlisted outcomes were presented in a 6 
matrix that covered the OMERACT core area headings of survival, life impact, resource 7 
use/economic, and pathophysiologic manifestations of cardiac arrest during CPR, 8 
immediately after CPR, during hospitalization, at hospital discharge, and within the first year 9 
after the cardiac arrest. Initial presentations were followed by semi-structured, small-group 10 
discussions that covered the 4 core areas. Each core area was assigned a facilitator who 11 
supported 4 rounds of discussions on that topic. Each discussion group included a survivor of 12 
cardiac arrest or patient advocate, as well as several researchers and clinicians who 13 
participated in small-group discussion across each core area. Each group nominated a 14 
recorder. The groups were tasked to consider the importance, relevance, acceptability, and 15 
feasibility of the short-listed outcomes as potential core outcomes for cardiac arrest 16 
effectiveness trials. The facilitator encouraged all group members to participate in 17 
discussions and shared key findings from each group with the next. This enabled 18 
consideration of and building upon what other participants discussed, facilitated the 19 
identification of issues of agreement and disagreement, and supported a flow of new ideas or 20 
key issues between groups. Participants, thereafter, reconvened in a whole-group discussion 21 
session: facilitators and group recorders summarized feedback from the group discussion, 22 
including areas of agreement and disagreement. The large-group discussion sought to 23 
collectively explore agreement and refine issues or concerns raised within each core area. At 24 
the end of the first day, expert panel members were invited to reflect on the day’s discussions 25 
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and then vote for up to 7 outcomes they felt should be included as core outcomes. Secure 1 
electronic votes were submitted by using Turningpoint Software and Responseware keypads 2 
(Turning Technologies, Youngstown, Ohio, USA). The second day followed a similar model 3 
of large- and small-group discussions designed to allow further discussion and reflection on 4 
the optimal outcomes. A second round of voting was used to identify the final list of core 5 
outcomes. Proceedings were captured in the form of detailed written records from discussion 6 
groups, plenary sessions, and the outcome of voting. 7 
 8 
[h2]Stage 4: Synthesis of Findings and Recommendations for Measurement Tools 9 
A writing group was appointed by ILCOR and endorsed by the American Heart Association 10 
Manuscript Oversight Committee after review for conflicts of interest. The charge to the 11 
group was to draw together and summarize the findings from stages 1 through 3. The group 12 
met by teleconference on 8 occasions and face-to-face on 1 occasion.  13 
 14 
The writing group reviewed and summarized the findings from stages 1 through 3 presented 15 
in this scientific statement. The group undertook further work with the intention of making 16 
recommendations on relevant measurement tools for the outcome domains selected in stage 17 
3. This was informed by considering existing measurement tools in cardiac arrest and other 18 
relevant diseases or injuries and discussing their quality, acceptability, and feasibility for 19 
application in clinical trials. Final recommendations were reached through discussion and 20 
consensus among the writing group members.  21 
 22 
  23 
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[h1]Results 1 
[h2]Stage 1: Generation of an Extensive List of Potential Outcomes Across 4 Core Areas 2 
(OMERACT Framework) 3 
The systematic review identified 61 randomized trials that reported 164 unique outcomes on 4 
278 occasions.11 The most frequently reported outcome was survival (85% of trials). This 5 
included return of spontaneous circulation (ROSC) before hospital admission, in the 6 
emergency department, or at any point during the resuscitation attempt. Survival was 7 
reported at various time points from emergency department admission, hospital discharge, 8 
and through to 3 years. There was a lack of consistency in definition and the time points at 9 
which survival was assessed, although most studies (90%) reported survival up to, and 10 
including, hospital discharge. Pathophysiologic outcomes (eg, coronary perfusion pressure, 11 
arterial blood gas results) and life impact were frequently reported, although there was a lack 12 
of consistency in outcomes, measurement tools, and the timings of assessments. Process of 13 
care (eg, event timings), response to treatment (eg, temperature achieved in targeted 14 
temperature management trials), quality of CPR, intervention success rates (eg, vascular 15 
access) and adverse outcomes were reported in a quarter of studies. Writing group members 16 
identified trials published more recently that reported outcomes in the domain of life 17 
impact.13, 14, 25, 26 18 
 19 
Eleven interviews (8 patients, 3 partners) were conducted to provide a detailed understanding 20 
of the lived experience of those surviving cardiac arrest. Five key themes were identified by 21 
patients reflecting the disruption to normality caused by cardiac arrest (survival, physical 22 
activities, emotional well-being, social well-being, and the impact on others; Table 1). 23 
  24 
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The findings from the systematic review and patient/partner interviews were used to produce 1 
an extensive list of 53 potential outcomes, encompassing survival (5), life impact (24), 2 
economic impact and resource use (10), and pathophysiologic manifestations (14), which 3 
were used in the stage 2 Delphi process. 4 
 5 
[h2]Stage 2: International Delphi to Refine and Prioritize Long List of Potential Outcomes 6 
Ninety-nine healthcare professionals, 62 cardiac arrest survivors and 7 relatives of cardiac 7 
arrest victims  from 15 countries participated in the Delphi survey. The clinician group 8 
included: 46 physicians, 12 nurses, 20 allied health professionals and 6 academics. By the 9 
end of the 2 Delphi rounds, 25 outcome domains were prioritized (Figure 2). 10 
 11 
[h2]Stage 3: International Expert Panel Meeting 12 
A total of 23 expert panel members (including 2 survivors, 1 partner, and 1 patient advocate) 13 
participated from 11 countries (UK, the Netherlands, Finland, Germany, Belgium, Sweden, 14 
United States, Canada, Singapore, Australia, and New Zealand). The core outcome 15 
discussions and recommendations are summarized below.  16 
 17 
[h3]Pathophysiologic Manifestations 18 
The expert panel considered circulatory function, respiratory function, and brain function as 19 
potential core outcomes. There was general agreement that the assessment of these outcomes 20 
is of high importance during and immediately after cardiac arrest. They become less 21 
important once ROSC has been achieved. Consideration was given to the potential for 22 
pathophysiologic measures to act as surrogate assessments for longer-term functional 23 
outcomes. For example, specific neuroimaging/electrophysiologic tests might be a useful 24 
surrogate to reflect the impact of a cardiac arrest on brain function.27 The panel considered 25 
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these outcomes may be valuable during the validation of new interventions and advancing 1 
discovery, for example, in efficacy trials. However, there was general agreement that the 2 
assessment of specific pathophysiologic manifestations as core outcomes across the wide 3 
range of effectiveness trials in this field is of limited value.  4 
 5 
The importance of reporting adverse events was discussed at length. There was general 6 
agreement that the reporting of adverse events should occur in accordance with Good Clinical 7 
Practice guidelines, which are relevant to all clinical trials, rather than as a core outcome 8 
specific for cardiac arrest.  9 
 10 
Although not introduced during the Delphi survey, participants discussed the importance of 11 
the quality of CPR (ie, CPR process) and its potential use as a core outcome. Such measures 12 
may include compression rate, pre-shock pause duration, compression depth, or time to 13 
intervention. There was unanimous consensus that the processes of CPR are important 14 
contributors to outcome after cardiac arrest. Participants recognized that CPR may be 15 
initiated or completed before a study intervention is applied. While CPR process may be an 16 
indicator of the quality of a resuscitation system of care or as a potential modifier of the 17 
effect of a study intervention, it was concluded that CPR process should not be a core 18 
outcome for effectiveness trials.  This should not limit researchers from reporting CPR 19 
quality matrices to enable the assessment of associations between CPR performance and Core 20 
Outcome Set categories.  Where such data are reported, use of standardised definitions 28 and 21 
time intervals may reduce variation in reporting.29 22 
 23 
[h3]Survival 24 
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The expert panel discussed the relative importance of short-term survival, such as ROSC. The 1 
outcome was thought to be important in efficacy studies, which seek to advance discovery in 2 
this field, but contributed less toward understanding longer-term aspects of survival.  3 
 4 
Hospital-free survival (number of days alive and permanently outside a hospital in the first 30 5 
days after cardiac arrest) was introduced during discussions. It was recently used in a large 6 
pragmatic cardiac arrest trial30 and offers potential statistical efficiencies over dichotomous 7 
outcomes.31, 32 Challenges can exist around the interpretation of a composite outcome, which 8 
combines survival with length of hospital stay.  9 
 10 
The panel concluded that longer-term survival (alive/dead) should be the core survival 11 
outcome. 12 
 13 
[h3]Life Impact 14 
Patient/partner participants voiced a number of potentially overlapping domains that may be 15 
affected after a cardiac arrest, which included cognition and consciousness, physical 16 
symptoms, activities of daily living, health-related quality of life (HRQoL), emotional well-17 
being, family impact, participation, and fatigue. It was agreed that one of the most common 18 
and significant impacts of cardiac arrest are potential changes to cognition and neurologic 19 
functioning. Other contributors to daily life such as physical, social, and emotional changes 20 
after returning home were discussed and considered important. To capture these important 21 
domains of health, a multi-domain approach, including assessing an individual’s HRQoL 22 
after arrest, was favored. 23 
 24 
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The panel reached consensus that neurologic function and HRQoL should be included as core 1 
outcomes.  2 
 3 
[h3]Economic Evaluation 4 
 5 
Although domains reflective of this core area were not prioritized by participants in the 6 
Delphi survey, the importance attributed to this core area in the OMERACT initiative 7 
suggested that further discussion of the relative importance of this core area and possible 8 
domains was required. Group discussion highlighted the complexities of capturing sufficient 9 
information to allow for a full economic analysis of costs related to cardiac arrest. While 10 
economic evaluation was judged to be important, it was agreed that there was insufficient 11 
evidence to inform categorization currently. As a result, economic measures are not being 12 
suggested as a core outcome.  13 
 14 
[h2]Stage 4: Recommendations for Measurement Tools and Timing of Measurement 15 
[h3]Survival 16 
Survival to discharge and survival to 30 days were considered to be better indicators of 17 
patient recovery than shorter-term survival, such as survival to admission or 4 to 6 hours after 18 
emergency department arrival. Discussion highlighted international variation in the feasibility 19 
of collecting survival at discharge and survival at 30 days. Both time points have limitations: 20 
survival to discharge is limited by cultural differences (whether patients are discharged home 21 
to die or die predominantly in hospital) and health system differences (efficiency of discharge 22 
processes; whether long-term care is provided in hospital or home care settings). This can 23 
limit comparisons across different health systems. Survival to specific intervals (eg, 30 days) 24 
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after arrest can avoid some of these limitations, but in some settings requires consent, which, 1 
as noted elsewhere, may introduce bias through higher rates of loss to follow-up.  2 
 3 
The writing group concluded that neither time point is perfect, and, for consistency with the 4 
Utstein recommendations,17 it was agreed either survival to hospital discharge or survival to 5 
30 days would be acceptable to report as core outcomes. Researchers are encouraged to 6 
report both measures if feasible, but should avoid reporting these as a composite outcome 7 
(survival to discharge or survival to 30 days) because this impairs pooling results in a meta-8 
analysis.  9 
 10 
[h3]Neurologic Function 11 
Five clinician-completed measures—the Cerebral Performance Category (CPC),33 Structured 12 
CPC (assessment by semi-structured interview),34 CPC-Extended,35 the Glasgow Outcome 13 
Scale–Extended (GOS-E),36 and modified Rankin Scale (mRS)37—were considered. 14 
Moderate associations between the tools suggest that they measure related, but not identical, 15 
constructs.13, 34, 38-41 The CPC was not highly endorsed because of the lack of discrimination 16 
between scores and the potential for ceiling effects and overestimation of function.14, 42-45 The 17 
CPC-Extended was considered to show good evidence of content validity, reliability, 18 
acceptability, and feasibility, although its use in cardiac arrest survivors was limited at this 19 
time.35 The mRS and GOS-E appear to provide improved granularity.40, 42 The mRS has been 20 
used more extensively in cardiac arrest survivors13, 40, 46-54 than the GOS-E43, 55 or CPC-21 
Extended have.36  22 
 23 
The writing group reached unanimous agreement that the mRS should be the outcome 24 
measurement tool of choice for neurologic function. The mRS is a brief, clinician-completed, 25 
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ordinal hierarchical rating scale used to determine a summary score of global disability56, 57 1 
after a neurologic event or condition. The mRS captures impairment of physical and 2 
cognitive abilities. Questions primarily focus on limitations in basic, instrumental, and more 3 
advanced daily activities and restrictions in ability to participate in normal social roles.57, 58 4 
There is evidence that it can discriminate between levels of mild and moderate disability.57 It 5 
does not, however, provide detailed information of residual impairments and is unable to 6 
differentiate between whether effects are due to neurologic or other sources of disability.57, 59 7 
 8 
[h3]How to Complete (Table 2) 9 
mRS completion is preferably measured by direct interview with the patient and any relevant 10 
caregiver—face-to-face or, optionally, by telephone.56 Non-standardized interview 11 
administration requires approximately 5 minutes.56 Where patients are unable to participate in 12 
interviews because of physical, language, or cognitive impairment, proxy completion—that 13 
is, completion by informants, such as family members, caregivers, or health professionals 14 
who know the patient well—may be considered. However, proxy completion without 15 
involving the patient is associated with suboptimal levels of reliability and validity.56, 60 16 
Although some studies suggest that indirect mRS completion from hospital records is less 17 
accurate,61 others suggest acceptable reliability following chart review by trained health 18 
professionals.35, 38 19 
 20 
Substantial inter-rater reliability of the mRS has been described,62 although this can be 21 
improved through digital training,62 use of a structured interview,58, 63 or use of a Web-based 22 
tool with 9 questions (mRS-9Q) and an mRS calculator.64 Use of trained raters as well as a 23 
structured approach to calculating the mRS score are recommended. Raters should optionally 24 
also be familiar with problems common after cardiac arrest. 25 
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 1 
[h3]Timing 2 
The advantages and disadvantages outlined above for reporting survival status at discharge or 3 
at 30 days apply similarly to the reporting of favorable neurologic function. Additional 4 
limitations of measuring neurologic function at discharge are that the patient will not have 5 
been exposed to normal/their previous activities to allow accurate determination of the 6 
relevant mRS category. The time of discharge is also likely to be influenced by the degree 7 
and speed of recovery, with those having the greatest disabilities remaining in hospital for 8 
longer. Additional challenges imposed by assessing neurologic function at 30 days is the 9 
requirement for the research team to specifically follow up with the patient because, unlike 10 
mortality, these data are not usually tracked routinely. Incomplete follow-up risks introducing 11 
attrition bias.  Whichever time-point is selected, the outcome should be reported as measured 12 
on the day of the assessment and not the best ever achieved.  13 
  14 
 15 
The writing group accepted that there were advantages and disadvantages to both time points, 16 
and similar to our suggestion for assessing survival status, mRS score at discharge or 30 days 17 
is considered acceptable for reporting as a core outcome. Researchers may report both time 18 
points if feasible but should avoid reporting as a composite outcome (mRS score at discharge 19 
or 30 days) because this impairs pooling results in a meta-analysis.  20 
 21 
[h3]What to report 22 
 23 
Historically cardiac arrest trials have dichotomized neurological outcomes into favorable or 24 
unfavorable categories based on a mRS cut off of <3.65-67 However in stroke trials a mRS of 25 
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<168 or < 269 has been used to represent the cut off between favorable and unfavorable 1 
outcomes. 2 
 3 
To enable consistent reporting and comparisons between papers, the writing group advised 4 
that the core outcome is presented as the number and percentages of patients in each of the 6 5 
categories rather than solely categorizing into favorable and unfavorable neurological 6 
outcome groups.  This approach also provides greater granularity on clinically relevant 7 
outcomes.70 8 
 9 
To facilitate the transition to mRS as the core outcome measurement tool and to support 10 
backward comparability, the writing group was also supportive of continued reporting of 11 
CPC score over the next 5 years, in addition to mRS score.  12 
 13 
Useful information for calculating the mRS score can be found at www.modifiedrankin.com. 14 
 15 
The COSCA writing group suggested the use of the mRS version, where category 4 16 
(moderate severe disability) is scored when the patient is either unable to attend to own 17 
bodily needs without assistance and/or unable to walk unassisted.  This better captures the 18 
level of disability for a patient with severe cognitive impairment, but still able to walk.  19 
Outcome after cardiac arrest is less influenced by locomotor problems when compared with 20 
stroke, and this version will be more sensitive to identify extensive dependency related 21 
to severe cognitive impairment in a patient still able to walk. This version is available at 22 
www.modifiedrankin.com. 23 
 0 = No symptoms 24 
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 1 = No significant disability. Able to carry out all usual activities, despite some 1 
symptoms 2 
 2 = Slight disability. Able to look after own affairs without assistance but unable to 3 
carry out all previous activities 4 
 3 = Moderate disability. Requires some help but able to walk unassisted 5 
 4 = Moderately severe disability. Unable to attend to own bodily needs without 6 
assistance and/or unable to walk unassisted 7 
 5 = Severe disability. Requires constant nursing care and attention, bedridden, 8 
incontinent 9 
 6 = Dead 10 
 11 
[h3]Health-Related Quality of Life 12 
The writing group spent considerable time deliberating which tools should be used to capture 13 
HRQoL after cardiac arrest. Key considerations were the relevance or acceptability to cardiac 14 
arrest survivors, feasibility (eg, ease of use, information collection methods), the 15 
measurement properties and their previous use in the cardiac arrest patient population, and 16 
cost. The writing group prioritized 6 generic measures of HRQoL for detailed consideration: 17 
2 multi-item profile measures (the Short-Form 36-Item Health Survey [SF-36]71 and Short 18 
Form 12-Item Health Survey [SF-12]72, 73) and 4 preference-based, multi-attribute utility 19 
measures (the 15-dimension Quality of Life questionnaire [15-D],74 the Health Utilities Index 20 
version 3 [HUI3],75 and both the original and revised versions of the EuroQol [EQ-5D-3L76 21 
and EQ-5D-5L,77 respectively]). All preference-based measures include both descriptive 22 
systems and a utility index, and hence, could be used in cost-utility evaluations.78  23 
 24 
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The group was unable to reach consensus and recommend a single tool among these 1 
measures. Patient and public partners highlighted that none of the tools comprehensively 2 
captured their experiences of the aftermath of a cardiac arrest. In online voting, the HUI3, 3 
followed by the SF-36 and EQ-5D-5L, received the most support (Table 3). The briefest 4 
measures are the EQ-5D-5L (5 items) and HUI3 (8 items); the longest is the SF-36 (v2) (36 5 
items). While all measures are intended to be measures of health status or HRQoL, the 6 
number of items and HRQoL coverage is varied (Table 3). The HUI3 and EQ-5D-5L have a 7 
preponderance of items that relate to physical health, whereas items within the SF-36(v2) are 8 
equally distributed between physical and mental health.78 However, only the HUI3 includes 9 
items that measure cognition, speech, and dexterity, which are concerns relevant to cardiac 10 
arrest survivors. Only the SF-36(v2) includes an assessment of fatigue.  11 
 12 
Preference-based utility scores can be calculated for HUI3, EQ-5D-5L, and SF-36(v2) (in the 13 
form of the SF-6D79), supporting their use in cost-utility evaluation. The SF-36(v2) provides 14 
the most detailed profile score—that is, separate scores are calculated across the 8 health 15 
domains, providing a more detailed assessment of health status than is otherwise afforded by 16 
the 2 summary scores. More limited descriptive profile scores can also be reported for both 17 
the HUI3 and EQ-5D across their 8 and 5 attributes, respectively. Normative population data 18 
are available for all measures, supporting data interpretation, and between-group 19 
comparisons. Estimates of meaningful change have been calculated for all measures 20 
following completion by the general population and specific patient groups, further 21 
supporting data interpretation. License requests are required for all measures, but only the 22 
EQ-5D-5L is free to use.  23 
 24 
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A review of published evidence on the reliability and validity of these measures following 1 
completion by survivors of cardiac arrest demonstrated that the strongest evidence was 2 
available for the HUI3, followed by the SF-36(v2).80 The EQ-5D-5L has not been evaluated 3 
in this population; however, evaluations in comparable populations suggest improved data 4 
quality and psychometric performance when compared with the original EQ-5D-3L.77  5 
 6 
In summary, multiple measures of HRQoL, including the SF-12(v2), SF-36(v2), EQ-5D-5L, 7 
and HUI3, are acceptable for measurement of outcomes in trials enrolling patients with 8 
cardiac arrest. Each of these has strengths and weaknesses compared with other measures 9 
available. HUI3 has been applied frequently to patients with cardiac arrest and directly 10 
measures cognition. The other measures are also acceptable. 11 
 12 
[h3]How to Complete 13 
Although all the above HRQoL measures were developed to be self-completed, all have been 14 
successfully interview-administered in person,39, 41 via the telephone,13, 55, 81, 82 or both14 in the 15 
cardiac arrest population. Postal self-completion, although possible has been only used 16 
infrequently. However, the ability to self-complete a questionnaire after a cardiac arrest can 17 
be severely impaired by cognitive impairment (which may result in an overestimation of 18 
ability),83 fatigue, or general poor health. Although proxy ratings of non-observable 19 
constructs such as emotional well-being and cognition may underestimate limitations,84, 85 20 
agreement is generally greater for more physical attributes.84, 86, 87 Cronberg et al described 21 
interview-based proxy completion of the SF-36(v2) with 8% of survivors at 6-month follow-22 
up.14 Where possible, proxy completion by appropriate, well-informed assessors is suggested 23 
to ensure that the views of survivors who are unable to self-report are included in trials and 24 
the results do not underestimate the impact of cardiac arrest on HRQoL.87  25 
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 1 
[h3]Timing 2 
There was consensus that HRQoL should be measured after the patient’s discharge from the 3 
hospital. Patient recovery often continues to 6 months and beyond. Three-quarters of patients 4 
of a working age return to work after cardiac arrest at a median interval of 4 months.88 The 5 
optimal time points and frequency of follow-up need to be considered in the context of study 6 
resources and overall study design. If sufficient resources are available to measure post-7 
discharge outcomes, the group recommends—as a minimum—assessment at 90 days. The 8 
group considered that this best balanced the trade-off between costs and other implications 9 
associated with longer-term follow-up with the positive effect of the value and stability of the 10 
data and is consistent with the review of primary outcomes by Becker et al.19 However, it is 11 
recognized that health status may continue to change in the subsequent months and that 12 
capturing this change is important.40, 88, 89 Therefore, the group agreed that HRQoL could also 13 
be assessed at 180 days and/or 1 year. However, the longer duration of follow-up would be 14 
associated with increased logistic challenges and may be influenced by factors external to 15 
surviving a cardiac arrest. 16 
 17 
[h1]Discussion 18 
The COSCA Writing Group identified that survival, neurologic function, and HRQoL should 19 
be reported as core outcomes in cardiac arrest effectiveness trials. Survival status should be 20 
reported at hospital discharge and / or at 30 days. Neurologic function (measured by using the 21 
mRS) should be reported at hospital discharge and / or 30 days. HRQoL should be measured 22 
by using 1 or more tools from the HUI3, SF-36(v2), or EQ-5D-5L at 90 days and at periodic 23 
intervals up to 1 year after cardiac arrest, if resources allow.  24 
 25 
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Core outcome sets are intended to enhance standardization of the outcomes, which are 1 
reported for effectiveness trials. As such, future cardiac arrest effectiveness trials should 2 
include the core outcomes identified by COSCA as part of the a priori‒designated primary or 3 
secondary trial outcomes. The COSs are intended to be complimentary to other outcome 4 
measures relevant to the particular intervention under evaluation. The COS recommendations 5 
sit alongside, rather than replace, tools designed to enhance the quality and transparency of 6 
health research, such as the Standard Protocol Items: Recommendations for Interventional 7 
Trials (SPIRIT)90 and Consolidated Standards of Reporting Trials91 (Figure 3). Earlier phase 8 
trials will typically focus primarily on measures of efficacy, such as biomarkers, ROSC, or 9 
immediate survival, although selected core outcomes could also be considered. 10 
 11 
Traditionally, outcome assessment of patients experiencing cardiac arrest has focused on 12 
survival rates and clinician-based assessments of outcome.11 However, the growth in patient-13 
centered care and recognition of the importance of seeking to understand the impact of 14 
cardiac arrest from the perspective of the survivor demand a shift in the way in which 15 
outcomes—in particular, over the longer-term—are assessed in clinical trials. The use of 16 
well-developed questionnaires, which provide an assessment of how patients feel, function, 17 
and live their lives because of their health and health care, can provide essential patient-18 
derived information to enhance outcome reporting in clinical trials.92 Such questionnaires or 19 
patient-reported outcome measures may be simply categorized as generic or specific (to a 20 
condition [eg, diabetes], a problem [eg, cognition], a function [eg, activities of daily life], or a 21 
population [eg, children]).  22 
 23 
Generic measure of HRQoL, such as those short-listed in the COSCA recommendations 24 
(HUI3, SF-36(v2), EQ-5D-5L), includes multidimensional concepts (physical, social, 25 
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emotional, and mental functioning) that provide a general assessment of HRQoL of relevance 1 
to patients and the general population, facilitating between-group comparisons and ensuring 2 
that the patient perspective is captured in clinical trials. Although the generic measures 3 
supported by COSCA start to move the focus toward patient-centered outcomes, the current 4 
tools still fail to comprehensively capture the breadth of outcomes and experiences that 5 
matter most to cardiac arrest survivors.93-95 As consequence, the impact of cardiac arrest and 6 
associated healthcare may be incompletely assessed. Although a condition-specific measure 7 
for survivors of cardiac arrest does not currently exist, measures specific to problems of 8 
relevance to cardiac arrest survivors (eg, cognition, fatigue, anxiety, social participation) are 9 
available and have been increasingly used in this population.13, 14, 25, 26, 96-98 Even though the 10 
COSCA recommendations do not currently include guidance for 1 or more problems or 11 
function-specific measures, per good practice guidance for outcome assessment,84, 85 where 12 
possible, we encourage their inclusion. Although not yet evaluated in the cardiac arrest 13 
population, the PROMIS initiative (Patient Reported Outcome Measures Information System 14 
http://www.healthmeasures.net/explore-measurement-systems/promis/intro-to-promis) 15 
describes a range of fixed or dynamic (computer adaptive tests) self-report measures of 16 
physical, mental and social health appropriate for use with the general population and those 17 
with chronic conditions, and hence suitable for comparing the burden of illness and treatment 18 
impact. The paucity of evidence to suggest which tools are best suited highlights the need for 19 
further research in this area.  20 
 21 
Collecting health-related quality-of-life measures as an outcome of a clinical trial can be 22 
challenging and expensive. Sometimes, such data are missing from patients with the poorest 23 
outcomes, which may result in systematic bias, which cannot be ignored.99, 100 To maximize 24 
the quality and timeliness of quality-of-life measures and reduce the risk of systematic bias 25 
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due to missing data, standardized administration and routine screening for avoidable missing 1 
data are advised.100-102 The approaches used and handling of missing data should be detailed 2 
in the study protocol and standard operating procedures.99, 101 3 
 4 
The writing group was cognizant of the balance that needs to be struck between the 5 
requirements of collecting the core outcomes identified by the COSCA initiative at a time of 6 
constrained research resources and the need to accelerate the pace of evidence-based change 7 
in resuscitation practices. The overall efficiency of the research pathway may be improved 8 
through a better understanding of the pathophysiology and effects of therapeutic interventions 9 
from animal and laboratory studies. By establishing proof of concept with evidence from 10 
early efficacy trials, internal pilots may reduce redundancy in effectiveness trials.103-105 11 
Improving the efficiency of the conduct of trials106 and making use, where possible, of 12 
registry data107 may reduce costs and shorten the time to complete trials. The use of fixed 13 
dichotomous analysis of ordered categorical outcomes is rarely the most statistically efficient 14 
approach and usually requires a larger sample size to demonstrate efficacy than other 15 
approaches.68 Alternative analytical approaches such as shift analysis, ordinal logistic 16 
regression, used widely in stroke research,68, 70 require further evaluation in the cardiac arrest 17 
population.   A better understanding of measurement properties of continuous outcomes, such 18 
as hospital-free survival,31 may also aid reductions in sample size and trial costs.  19 
 20 
[h1]Conclusion 21 
Through a partnership between patients, partners, clinicians, and researchers and endorsed by 22 
ILCOR, consensus emerged that a core outcome set for reporting on effectiveness studies of 23 
cardiac arrest (COSCA) should include survival, neurologic function, and health-related 24 
quality of life (HRQoL). To facilitate meaningful comparisons across studies over time, 25 
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survival status and modified Rankin scale at hospital discharge and / or 30 days should be 1 
reported. HRQoL should be measured by using 1 or more tools from the HUI3, SF-36(v2), or 2 
EQ-5D-5L at 90 days and at periodic intervals up to 1 year after cardiac arrest, if resources 3 
allow.  4 
 5 
  6 
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Table 1. Themes From Patient and Partner Interviews Relating to Disruption to 1 
Normality 2 
Theme Examples 
Survival Closeness to death  
Gratitude to be alive  
Impairment and impact to 
activities 
Fatigue  
Breathlessness  
Vision  
Muscle weakness  
Pain (eg, fractured ribs) 
Activities of daily living/increased 
dependence  
Cognitive function 
Emotional well-being Anxiety  
Confidence  
Depression  
Self-esteem  
Personality changes  
Frustration  
Social well-being and 
participation 
Participation (role: job, voluntary, career)  
Participation (leisure: hobbies, sports)  
Participation (social activities)  
Participation (family: relationships, intimacy)  
Impact on others Increased work/care  
Impact to participation—hobbies, work  
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Strain on relationships  
Worry  
 1 
 2 
 3 
 4 
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Table 2. Core outcomes, time-point and preferred methods for collection 
 
Outcome Time-point Preferred method Alternative method 
Survival 30 days and / or 
discharge 
Ambulance / Hospital 
records 
Death registry 
  
Neurological function 
(mRS) 
30 days and / or 
discharge 
Face to face interview by 
trained raters using mRS-
9Q 
Informant interview 
Telephone assessment 
Review of hospital 
records 
  
Quality of Life 90 days Face-to-face 
(proxy completion where 
respondents are unable 
to participate) 
 
Telephone interviews 
Postal questionnaire 
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Table 3. Summary and Item Content of Short-listed Generic HRQoL Measures (n=3) 
PROM  
 
Developer 
Website 
Cost (License) 
Completion Time 
 
Conceptual Focus, 
Response Options/Recall Period, Completion 
Format, 
Language Versions 
HRQoL Domains (Ferrans et al, 2005) 
(Items Per Domain) 
 
How to Score 
Symptom 
Status 
 
Symptoms 
Functional Status General 
Health 
Perception 
Physical Cognitive Psychological Social/Role 
 
Preferences based (2) 
 
        
Health Utilities Index 3  
 
(HUI3) 
 
www.healthutilities.com 
 
License for use per project; 
minimum fee $3000 (US) [Horsman, 
2003] 
 
Completion time: 
Approximately 8 minutes self-
completion 
Preference-based, comprehensive system for 
measuring health status and HRQoL and for 
producing utility scores. Applicable for all persons 
aged 5 years and older. 
 
HUI3 classification system: describes the 
comprehensive health state of an individual across 8 
attributes of general health (6/8 items reflect 
physical functional status) 
 
Response options: Between 4 and 6 descriptive 
response options (ability/disability) 
 
Pain—severity 
(1) 
Ambulation: 
Ability to 
walk 
(distances) 
 
Dexterity: 
Ability to 
use hands 
and fingers 
 
Senses: 
Vision 
 
Cognition: 
ability to 
solve day-
to-day 
problems 
(1) 
Emotion: 
happiness and 
interest in life 
(1) 
  2 ways of 
presenting the 
data: 
 
1. HUI3 utility 
index: scored 
by using 
single- and 
multiattribute 
utility 
functions 
 
HUI-specific 
coding 
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Approximately 3 minutes interview 
completion 
(not reported in cardiac arrest 
population) 
 
 
User guide: Available once HUI3 is 
purchased  
 
Country of origin: Canada 
 
Recall period: “Current” or “Usual” —“Usual” 
recommended for clinical studies. Choice of 1-
week, 2-week, or 4-week recall available. (Horsman 
et al, 2003) 
 
Completion: Self, interview (in person; telephone), 
or proxy (proxy version available) supported 
 
Language: 16 versions, including English, Chinese, 
Dutch, French, German, Italian, Japanese, 
Portuguese, Russian, Spanish, Swedish 
 
Senses: 
Hearing 
 
Speech: 
Ability to be 
understood 
 
(5) 
 
algorithms to 
support 
calculation of 
single-
attribute 
Utility Score 
(Index) 
 
Index range –
0.36 to 1.00, 
where 1.00 is 
perfect health, 
0 is dead, and 
<0 is a health 
state worse 
than death 
 
Population-
based norms 
available 
 
2. 
Multiattribute 
descriptive 
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system— 
“Classification 
system”—
reflects 
individual 
item scores  
EuroQol EQ-5D-5L 
 
(EQ-5D-5L) 
 
www.euroqol.org/home.html 
 
 
License: For use per project; free, 
but use must be registered on 
EuroQol website: 
www.euroqol.org/register-to-use-eq-
5d.html 
 
 
Completion time: 
Less than 5 minutes 
(not reported in cardiac arrest 
population) 
Standardized, preference-based measure of health 
status for use in clinical and economic appraisal 
 
EQ-5D descriptive system: 5 items across “5 
domains” (2/5 reflects physical functional status) 
 
(EQ VAS: self-rated health on a 20 cm vertical 
visual analogue scale) 
 
Response options: 5-level categorical response 
options per item (no problems [1] to extreme 
problems [5]) 
 
Completion of all items will produce a 5-digit 
number describing the respondent’s health state (but 
the numerals 1–5 have no inherent arithmetic 
properties and should not be used as a cardinal 
score) 
Pain/discomfort 
(1) 
 
Mobility 
 
Self-care 
 
(2) 
 
– Anxiety/depression 
(1) 
Usual 
activities 
(including 
work, 
study, 
housework, 
and family 
or leisure 
activities) 
(1) 
 
– 2 ways of 
presenting the 
data: 
 
1. EQ-5D-5L 
Index value 
EuroQol-
specific 
coding 
algorithms to 
support 
calculation of 
Utility Score 
(Index):  
 
Crosswalk 
value sets 
from EQ-5D-
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User guide: Free at following link: 
www.euroqol.org/about-eq-
5d/publications/user-guide.html 
 
Country of origin: Multiple 
 
 
Recall period: Today 
 
Completion: Self, interview (in person, telephone), 
or proxy (2 proxy versions) supported: 
www.euroqol.org/about-eq-5d/modes-of-
administration.html 
 
Formats: PDA, pen and paper, proxy paper, tablet, 
telephone, Web: 
www.euroqol.org/eq-5d-products/eq-5d-5l.html 
 
Language: >120 language versions (see 
www.euroqol.org) 
 
 
 
 
 
3L support 
calculation of 
EQ-5D-5L 
utility score 
 
Index range –
0.59 to 1.00, 
where 1.00 is 
perfect quality 
of life, 0 is 
death, and <0 
is a health 
state worse 
than death 
 
Country-
specific value 
sets and 
population-
based norms 
available 
 
Report both 
measure of 
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central 
tendency and 
a measure of 
dispersion, eg, 
mean and SD; 
median and 
percentiles 
 
2. EQ-5D-5L 
descriptive 
system as a 
health profile: 
reflects 
individual 
item scores.  
2.1 Report as 
the frequency 
or proportion 
of reported 
problems for 
each level for 
each 
dimension 
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2.2 
Dichotomize 
into “No 
problems” (1) 
and 
“Problems” 
(2–5), report 
frequencies of 
reported 
problems 
 
 
Profile measures (1) 
 
        
Short Form 36-Item Health 
Survey, version 2 
 
(SF-36v2) 
 
https://campaign.optum.com/optum-
outcomes/what-we-do/health-
surveys/sf-36v2-health-survey.html 
 
Functional health and well-being from the patient’s 
perspective—underpinned by 8 health domains 
across both physical (4) and mental (4) aspects of 
health 
 
Total 35 items plus 1 health transition item 
 
Response options: Between 3- and 6-level 
categorical response options per item 
 
Bodily pain 
(BP) (2) 
 
Vitality (VT): 
fatigue/tiredness 
(2) 
Physical 
functioning 
(PF) (10) 
 
Role 
limitation 
(RP) (4) 
– Mental health 
(MH) (5)  
 
Role limitation 
(RE) (3) 
Social 
functioning 
(SF) (2) 
General 
health 
(GH) (5): 
perceived 
well-being 
2 ways of 
presenting the 
data:  
 
2.1 Eight-
domain profile 
 
2.2 Two 
component 
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License For use per project; 
minimum fee $US 
 
Survey license request: via above 
URL 
 
Completion time: 
Range 5 to 30 minutes 
(not reported in cardiac arrest 
population) 
 
 
User guide: Available once SF-36v2 
is purchased  
 
Country of origin: United States 
 
Recall period: Standard recall 4 weeks; acute recall 
1 week 
 
Completion: Self, interview (in person; telephone), 
or proxy supported 
 
Language: >170 language versions:  
See website 
 
The IQOLA project supported the development of 
conceptually equivalent and culturally appropriate 
translations (see www.iqola.org) 
 
Note: utility values 
A preference-based utility index, the SF-6D can be 
calculated after completion of the SF-36 to inform 
economic analyses: 
 
https://www.shef.ac.uk/scharr/sections/heds/mvh/sf-
6d 
summary 
scales:  
PCS,  
MCS 
 
Scoring 
requires SF-
36–specific 
algorithm. 
 
Norm-based 
scoring: score 
transformed to 
0–100 (mean 
50 [SD 10])  
 
Population-
based norms 
available 
 
 
EQ VAS indicates EuroQol visual analogue scale; HRQoL, health-related quality of life; IQOLA, International Quality of Life Assessment; 
MCS, mental component summary; PCS, physical component summary; PROM, patient-reported outcome measure; SD, standard deviation; 
VAS, visual analogue scale. 
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Figure 1. OMERACT framework 2.0 modified for cardiac arrest.  
ICU indicates intensive care unit; QoL, quality of life; and ROSC, return of spontaneous 
circulation. 
Republished with permission of Elsevier, from Boers M, Kirwan JR, Wells G, et al. J Clin 
Epidemiol. 2014;67(7):745-753; permission conveyed through Copyright Clearance Center, 
Inc. 
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Core Area Outcome Domain Timing of Measurement 
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Pathophysiologic 
manifestations 
Circulatory function  
   
  
Respiratory function    
 
  
Renal function       
Brain function (neurologic markers) 
 
 
    
Adverse events  
 
    
 
CPR process measures* 
 
     
Survival  Survival  
     
Life impact Consciousness and cognition       
Physical symptoms    
  
Activities of daily living    
  
Health-related quality of life    
  
Emotional well-being      
 
Family impact      
 
Participation    
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Fatigue      
 
Economic impact and 
resource use 
Cost-effectiveness       
Hospital-free survival*       
 
Figure 2: Outcome domains presented for discussion at COSCA meeting.  
Symbol key: Circles indicate healthcare professionals and researchers. Triangles indicate 
patients and partners. Gray fill indicates strong consensus (<70%); white fill indicates 
moderate support. Gray boxes were not rated or ranked on their importance.  
*Hospital-free survival and CPR process measures were introduced during expert panel 
meeting. 
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Figure 3. Clinical trials are conducted within the overall framework of good clinical 
practice, which supports clear and transparent reporting. Core outcome sets are 
suggested for inclusion as part of the a priori‒designated primary or secondary end 
points of effectiveness trials. They enhance the quality and transparency of health 
research promoted by SPIRIT and CONSORT.  
QoL indicates quality of life. 
 
